Iranian Red Crescent Medical Journal

Published by: Kowsar
Crossmark

In vitro and in vivo Assessment of Anti-Leishmanial Efficacy of Leaf, Fruit, and Fractions of Juniperus excelsa Against Axenic Amastigotes of Leishmania major and Topical Formulation in BALB/c Mice

Somayeh Mirzavand 1 , Gholamreza Hatam 1 , * , Mahmoodreza Moein 2 and Mohammad M Zarshenas 2
Authors Information
1 Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2 Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Article information
  • Iranian Red Crescent Medical Journal: 21 (6); e87754
  • Published Online: June 8, 2019
  • Article Type: Research Article
  • Received: December 17, 2018
  • Revised: May 11, 2019
  • Accepted: May 13, 2019
  • DOI: 10.5812/ircmj.87754

To Cite: Mirzavand S, Hatam G, Moein M, Zarshenas M M. In vitro and in vivo Assessment of Anti-Leishmanial Efficacy of Leaf, Fruit, and Fractions of Juniperus excelsa Against Axenic Amastigotes of Leishmania major and Topical Formulation in BALB/c Mice, Iran Red Crescent Med J. Online ahead of Print ; 21(6):e87754. doi: 10.5812/ircmj.87754.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Aronson NE, Joya CA. Cutaneous leishmaniasis: Updates in diagnosis and management. Infect Dis Clin North Am. 2019;33(1):101-17. doi: 10.1016/j.idc.2018.10.004. [PubMed: 30712756].
  • 2. Akhoundi M, Kuhls K, Cannet A, Votypka J, Marty P, Delaunay P, et al. A historical overview of the classification, evolution, and dispersion of leishmania parasites and sandflies. PLoS Negl Trop Dis. 2016;10(3). e0004349. doi: 10.1371/journal.pntd.0004349. [PubMed: 26937644]. [PubMed Central: PMC4777430].
  • 3. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5). e35671. doi: 10.1371/journal.pone.0035671. [PubMed: 22693548]. [PubMed Central: PMC3365071].
  • 4. Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951-70. doi: 10.1016/S0140-6736(18)31204-2. [PubMed: 30126638].
  • 5. Ardehali S, Moattari A, Hatam GR, Hosseini SM, Sharifi I. Characterization of Leishmania isolated in Iran: 1. Serotyping with species specific monoclonal antibodies. Acta Trop. 2000;75(3):301-7. doi: 10.1016/S0001-706X(00)00064-4. [PubMed: 10838213].
  • 6. Shirian S, Oryan A, Hatam GR, Daneshbod K, Daneshbod Y. Molecular diagnosis and species identification of mucosal leishmaniasis in Iran and correlation with cytological findings. Acta Cytol. 2012;56(3):304-9. doi: 10.1159/000337450. [PubMed: 22555534].
  • 7. Badirzadeh A, Mohebali M, Ghasemian M, Amini H, Zarei Z, Akhoundi B, et al. Cutaneous and post kala-azar dermal leishmaniasis caused by Leishmania infantum in endemic areas of visceral leishmaniasis, northwestern Iran 2002-2011: A case series. Pathog Glob Health. 2013;107(4):194-7. doi: 10.1179/2047773213Y.0000000097. [PubMed: 23816511]. [PubMed Central: PMC4001470].
  • 8. Badirzadeh A, Mohebali M, Sabzevari S, Ghafoori M, Arzamani K, Seyyedin M, et al. Case report: First coinfection report of mixed leishmania infantum/leishmania major and human immunodeficiency virus-acquired immune deficiency syndrome: Report of a case of disseminated cutaneous leishmaniasis in Iran. Am J Trop Med Hyg. 2018;98(1):122-5. doi: 10.4269/ajtmh.17-0490. [PubMed: 29165208]. [PubMed Central: PMC5928724].
  • 9. Rocha LG, Almeida JR, Macedo RO, Barbosa-Filho JM. A review of natural products with antileishmanial activity. Phytomedicine. 2005;12(6-7):514-35. doi: 10.1016/j.phymed.2003.10.006. [PubMed: 16008131].
  • 10. Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, Lopez-Velez R, Garcia-Hernandez R, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017;11(12). e0006052. doi: 10.1371/journal.pntd.0006052. [PubMed: 29240765]. [PubMed Central: PMC5730103].
  • 11. Machado M, Santoro G, Sousa MC, Salgueiro L, Cavaleiro C. Activity of essential oils on the growth of Leishmania infantum promastigotes. Flavour Fragr J. 2010;25(3):156-60. doi: 10.1002/ffj.1987.
  • 12. Zahedifard F, Lee H, No JH, Salimi M, Seyed N, Asoodeh A, et al. Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentials. PLoS Negl Trop Dis. 2019;13(2). e0007217. doi: 10.1371/journal.pntd.0007217. [PubMed: 30811391]. [PubMed Central: PMC6411200].
  • 13. Kolodziej H, Kiderlen AF. Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells. Phytochemistry. 2005;66(17):2056-71. doi: 10.1016/j.phytochem.2005.01.011. [PubMed: 16153409].
  • 14. Ozkan K, Gulsoy S, Aerts R, Muys B. Site properties for Crimean juniper (Juniperus excelsa) in semi-natural forests of south western Anatolia, Turkey. J Environ Biol. 2010;31(1-2):97-100. [PubMed: 20648818].
  • 15. Sela F, Karapandzova M, Stefkov G, Cvetkovikj I, Kulevanova S. Chemical composition and antimicrobial activity of essential oils of Juniperus excelsa Bieb. (Cupressaceae) grown in R. Macedonia. Pharmacognosy Res. 2015;7(1):74-80. doi: 10.4103/0974-8490.147212. [PubMed: 25598638]. [PubMed Central: PMC4285653].
  • 16. Karaman I, Sahin F, Gulluce M, Ogutcu H, Sengul M, Adiguzel A. Antimicrobial activity of aqueous and methanol extracts of Juniperus oxycedrus L. J Ethnopharmacol. 2003;85(2-3):231-5. doi: 10.1016/S0378-8741(03)00006-0. [PubMed: 12639746].
  • 17. Samoylenko V, Dunbar DC, Gafur MA, Khan SI, Ross SA, Mossa JS, et al. Antiparasitic, nematicidal and antifouling constituents from Juniperus berries. Phytother Res. 2008;22(12):1570-6. doi: 10.1002/ptr.2460. [PubMed: 19067375].
  • 18. Ozturk M, Tumen I, Ugur A, Aydogmus-Ozturk F, Topcu G. Evaluation of fruit extracts of six Turkish Juniperus species for their antioxidant, anticholinesterase and antimicrobial activities. J Sci Food Agric. 2011;91(5):867-76. doi: 10.1002/jsfa.4258. [PubMed: 21384354].
  • 19. El Omari K, Hamze M, Alwan S, Osman M, Jama C, Chihib NE. In-vitro evaluation of the antibacterial activity of the essential oils of Micromeria barbata, Eucalyptus globulus and Juniperus excelsa against strains of Mycobacterium tuberculosis (including MDR), Mycobacterium kansasii and Mycobacterium gordonae. J Infect Public Health. 2019. doi: 10.1016/j.jiph.2019.01.058. [PubMed: 30738755].
  • 20. Khan M, Khan AU, Najeeb ur R, Gilani AH. Pharmacological explanation for the medicinal use of Juniperus excelsa in hyperactive gastrointestinal and respiratory disorders. J Nat Med. 2012;66(2):292-301. doi: 10.1007/s11418-011-0605-z. [PubMed: 22134420].
  • 21. Shirazi AA. Makhzan al-adviyah (The Storehouse of Medicaments). Tehran, Iran: Tehran University of Medical Sciences; 2009.
  • 22. Moein M, Hatam G, Taghavi-Moghadam R, Zarshenas MM. Antileishmanial activities of Greek Juniper (Juniperus excelsa M.Bieb.) against leishmania major promastigotes. J Evid Based Complementary Altern Med. 2017;22(1):31-6. doi: 10.1177/2156587215623435. [PubMed: 26747836]. [PubMed Central: PMC5871199].
  • 23. Parvizi MM, Handjani F, Moein M, Hatam G, Nimrouzi M, Hassanzadeh J, et al. Efficacy of cryotherapy plus topical Juniperus excelsa M. Bieb cream versus cryotherapy plus placebo in the treatment of Old World cutaneous leishmaniasis: A triple-blind randomized controlled clinical trial. PLoS Negl Trop Dis. 2017;11(10). e0005957. doi: 10.1371/journal.pntd.0005957. [PubMed: 28981503]. [PubMed Central: PMC5655399].
  • 24. Topcu G, Erenler R, Cakmak O, Johansson CB, Celik C, Chai HB, et al. Diterpenes from the berries of Juniperus excelsa. Phytochemistry. 1999;50(7):1195-9. doi: 10.1016/S0031-9422(98)00675-X. [PubMed: 10234860].
  • 25. Chan-Bacab MJ, Pena-Rodriguez LM. Plant natural products with leishmanicidal activity. Nat Prod Rep. 2001;18(6):674-88. [PubMed: 11820764].
  • 26. Habibi P, Sadjjadi SM, Owji M, Moattari A, Sarkari B, Naghibalhosseini F, et al. Characterization of in vitro cultivated amastigote like of Leishmania major: a substitution for in vivo studies. Iran J Parasitol. 2008;3(1):6-15.
  • 27. Nahrevanian H, Farahmand M, Aghighi Z, Assmar M, Amirkhani A. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis. Exp Parasitol. 2007;116(3):233-40. doi: 10.1016/j.exppara.2007.01.002. [PubMed: 17335813].
  • 28. Van den Kerkhof M, Mabille D, Chatelain E, Mowbray CE, Braillard S, Hendrickx S, et al. In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series. Int J Parasitol Drugs Drug Resist. 2018;8(1):81-6. doi: 10.1016/j.ijpddr.2018.01.006. [PubMed: 29425734]. [PubMed Central: PMC6114106].
  • 29. Wong IL, Chan KF, Chen YF, Lun ZR, Chan TH, Chow LM. In vitro and in vivo efficacy of novel flavonoid dimers against cutaneous leishmaniasis. Antimicrob Agents Chemother. 2014;58(6):3379-88. doi: 10.1128/AAC.02425-13. [PubMed: 24687505]. [PubMed Central: PMC4068441].
  • 30. Shimony O, Jaffe CL. Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods. 2008;75(2):196-200. doi: 10.1016/j.mimet.2008.05.026. [PubMed: 18573286].
  • 31. Nuhs A, De Rycker M, Manthri S, Comer E, Scherer CA, Schreiber SL, et al. Development and validation of a novel leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of leishmanicidal intracellular activity. PLoS Negl Trop Dis. 2015;9(9). e0004094. doi: 10.1371/journal.pntd.0004094. [PubMed: 26407168]. [PubMed Central: PMC4583543].
  • 32. Castillo D, Arevalo J, Herrera F, Ruiz C, Rojas R, Rengifo E, et al. Spirolactone iridoids might be responsible for the antileishmanial activity of a Peruvian traditional remedy made with Himatanthus sucuuba (Apocynaceae). J Ethnopharmacol. 2007;112(2):410-4. doi: 10.1016/j.jep.2007.03.025. [PubMed: 17459622].
  • 33. Shuaibu MN, Pandey K, Wuyep PA, Yanagi T, Hirayama K, Ichinose A, et al. Castalagin from Anogeissus leiocarpus mediates the killing of Leishmania in vitro. Parasitol Res. 2008;103(6):1333-8. doi: 10.1007/s00436-008-1137-7. [PubMed: 18690475].
  • 34. Eltayeb A, Ibrahim K. Potential antileishmanial effect of three medicinal plants. Indian J Pharm Sci. 2012;74(2):171-4. doi: 10.4103/0250-474X.103856. [PubMed: 23326001]. [PubMed Central: PMC3546337].
  • 35. Dua VK, Verma G, Agarwal DD, Kaiser M, Brun R. Antiprotozoal activities of traditional medicinal plants from the Garhwal region of North West Himalaya, India. J Ethnopharmacol. 2011;136(1):123-8. doi: 10.1016/j.jep.2011.04.024. [PubMed: 21527328].
  • 36. Rahman K, Khan SU, Fahad S, Shinwari ZK, Khan D, Kamal S, et al. In vitro biological screening of a critically endangered medicinal plant, Atropa acuminata Royle Ex Lindl of north western Himalaya. Sci Rep. 2018;8(1):11028. doi: 10.1038/s41598-018-29231-x. [PubMed: 30038240]. [PubMed Central: PMC6056422].
  • 37. Ghosh S, Debnath S, Hazra S, Hartung A, Thomale K, Schultheis M, et al. Valeriana wallichii root extracts and fractions with activity against Leishmania spp. Parasitol Res. 2011;108(4):861-71. doi: 10.1007/s00436-010-2127-0. [PubMed: 21085992].
  • 38. dos Santos AO, Costa MA, Ueda-Nakamura T, Dias-Filho BP, da Veiga-Junior VF, de Souza Lima MM, et al. Leishmania amazonensis: Effects of oral treatment with copaiba oil in mice. Exp Parasitol. 2011;129(2):145-51. doi: 10.1016/j.exppara.2011.06.016. [PubMed: 21771592].
  • 39. van Tonder A, Joubert AM, Cromarty AD. Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays. BMC Res Notes. 2015;8:47. doi: 10.1186/s13104-015-1000-8. [PubMed: 25884200]. [PubMed Central: PMC4349615].
  • 40. Muelas-Serrano S, Nogal-Ruiz JJ, Gomez-Barrio A. Setting of a colorimetric method to determine the viability of Trypanosoma cruzi epimastigotes. Parasitol Res. 2000;86(12):999-1002. doi: 10.1007/PL00008532. [PubMed: 11133116].
  • 41. Hatam GR, Rezanezhad H, Motazedian MH, Sarkari B. In vitro infectivity of Leishmania major isolated from patients with different clinical forms of cutaneous leishmaniasis and its association with parasite zymodems. Iran J Parasitol. 2009;4(3):52-60.

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments